TY  - GEN
AU  - Bakker,Jan
AU  - Grover,Robert
AU  - McLuckie,Angela
AU  - Holzapfel,Laurent
AU  - Andersson,Jan
AU  - Lodato,Robert
AU  - Watson,David
AU  - Grossman,Steven
AU  - Donaldson,Jill
AU  - Takala,Jukka
TI  - Administration of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002)
SN  - 0090-3493
PY  - 2004///0212
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Critical Care
KW  - methods
KW  - Dose-Response Relationship, Drug
KW  - Double-Blind Method
KW  - Drug Administration Schedule
KW  - Female
KW  - Follow-Up Studies
KW  - Hemodynamics
KW  - drug effects
KW  - Humans
KW  - Infusions, Intravenous
KW  - Intensive Care Units
KW  - Male
KW  - Middle Aged
KW  - Nitric Oxide Synthase
KW  - antagonists & inhibitors
KW  - Oxygen Consumption
KW  - Probability
KW  - Reference Values
KW  - Risk Assessment
KW  - Severity of Illness Index
KW  - Shock, Septic
KW  - drug therapy
KW  - Survival Analysis
KW  - Treatment Outcome
KW  - omega-N-Methylarginine
KW  - administration & dosage
N1  - Publication Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1097/01.CCM.0000105118.66983.19
ER  -